TCGA database findings indicated that the ZFP36 high expression group had markedly high survival rates free from postoperative biochemical recurrence and metastasis biochemical recurrence than the ZFP36 low expression group (Figure 1(e), P < 0.05); in the Taylor database and the ZFP36 high expression group, the postoperative biochemical recurrence-free survival and metastasis-free survival were markedly higher compared with the ZFP36 low expression group (Figure 1(f), P < 0.05), indicating that ZFP36 could suppress cancer in prostate tumors. This evidence concerns the gene ZFP36 and prostate neoplasm.